Zimmer Biomet boosts foot-and-ankle biz with Nextremity distribution deal

Zimmer Biomet is adding to its foot-and-ankle stable with a global distribution deal for Nextremity Solutions’ deformity correction devices.

Under the agreement, Zimmer Biomet will distribute Nextremity’s implants for the correction of foot and ankle deformities, including the Nextra Hammertoe Correction System, an adjustable, two-piece hammertoe implant, and the Metatarsal Shortening System, which is a bone-cutting guide and implant in one. Zimmer Biomet will also market Nextremity’s bunion correction system and staple system, according to a statement. Financial details were not disclosed.

The Nextremity devices will complement Zimmer Biomet’s Foot and Ankle System, an implant and instrument system for the reconstruction or replacement of the ankle joint.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

"The agreement helps advance our commitment to provide customers with the broadest range of cutting-edge technologies and strengthens our position in the $2 billion foot and ankle market,” said Brad Quick, general manager of Zimmer Biomet’s foot and ankle unit, in the statement.

Following the $13.4 billion acquisition that created Zimmer Biomet, the company has been reaching into its deep pockets to make M&A moves. In June, it threw down a whopping $1 billion for spinal surgery player, LDR Systems, in a bid to boost its spine division. And in July, Zimmer Biomet splashed into robotic surgery with its acquisition of France’s Medtech for about $132 million.


Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.